Fukui et al. CorEvitas study. 12076 RA patients. Propensity score matching. Kidney dysfunction (eGFR<60) reduced chance of CDAI remission (HR 0.71) or remission/LDA (HR 0.88) @RheumNow #ACR25 Abstr#2640 https://t.co/uvTjOQlGD7

Dr. LRoss presents the SCTC SSc Heart Involvement classification criteria ♥️Criteria score >/= 11pts 🔸SN 77.8%; SP 95.9% 🔸OR 82.6 Huge endeavor towards standardization of SHI to help improve patient outcomes in the future 👏👏 #ACR25 @RheumNow https://t.co/QrgYlksjZB

Sjögren’s: two Phase 3 RCTs (NEPTUNUS-1 [QM], -2 [Q3M]) test Ianalumab (BAFF/BAFF-R) vs placebo. ΔESSDAI at 48wk: Ianalumab QM > PBO, statistically significant But ΔESSDAI ≈ 0.5–1 pt (vs PBO) below MCII (≥ 3) Promising biology, modest clinical gain #ACR25 @RheumNow LB24 https://t.co/8y580ch9iJ

Sjogren’s disease: is it maybe true you need to still have some salivary function left to get benefit from therapy? Ianalumab (BAFF inh) ph3 NEPTUNUS-1/2 Very decent on primary (ESSDAI) & we will see this Salivary flow only improved when some at baseline #ACR25 LB24 @RheumNow https://t.co/uGwKdN3Dsh

#ACR25 Abstr#LB24 The first Phase 3 RCTs in #Sjogren meeting primary endpoint! In moderate-to-severe activity, both RCTs = improvement in ESSDAI vs PBO (pooled effect -1.2 reduction). High PBO rate. PGA, PaGA & Stimulated Salivary Flow) improved. No diff in ESSPRI/FACIT @RheumNow https://t.co/rAs6NeXDIn

Use of AI in AxSpA imaging for diagnosis. ASembleNet, a hybrid deep learning model, achieved 99% accuracy on coronal and 98.1% on axial MRI for AS classification, outcomes higher than ResNet50, Xception, and InceptionV3. Validated on ASAS cases, with Grad-CAM interpretability and https://t.co/yU8shaIdP2

Grader-Beck et al. Ianalumab in Sjogren's disease. NEPTUNUS 1 and 2 studies. 779 patients. Met primary endpoint ESSDAI. Big placebo effect also. Patient and physician global also improved. @RheumNow #ACR25 Abstr#LB24 https://t.co/klhxXW4Jfh

Fighting fire with butyrate 🔥🚒 ♦️probiotics and prebiotics Dr. Nisha Manek on inflammation and butyrate - it reduces gut inflamm thru the NFKB pathway #ACR25 @RheumNow https://t.co/19XTrKn1iN

Autologous CAR-Treg in RA, without any lymphodepletion preRx Early data from ph1, single dose Good initial response, stopped RA Rx, but some rebound Clearly work ongoing but excitement re: - CAR-Treg - RA as target dx - no lymphodepletion @minnakohlermd #ACR25 LB23 @RheumNow https://t.co/azmlFNU02R

REGULATE RA SBT-77-701 Engineered Treg cell in Refractory RA population 6patients Safety and tolerability: No DLT, CRS or ICANS Efficacy Reduction >50% in TJC and SJC 67% reduction of DAS-CRP >=2 stained up to wk 24 Impressive in pts for whom it works, yet a couple seem to https://t.co/lQAQABPhg0

Useful clinical pearls by @Janetbirdope on ANA testing @RheumNow #ACR25 #ACRBest https://t.co/1FMv5nIWNe

Kohler et al. Phase 1 study autologous CAR-Tregs in refractory RA. No lymphodepletion needed! 6 participants. 2 doses, second cohort with higher dose better and more sustained response. No CRS or other toxicities. @RheumNow #ACR25 Abstr#LB023 https://t.co/nWva2R7WOQ